García-Delgado D

Language: English
References: 14
Page: 243-248
PDF size: 244.16 Kb.

ABSTRACT

Intangible assets may involve more than 2/3 of the value of enterprises and even higher, as in the case of high tech enterprises where knowledge is the main asset. Almost 70 % of the intangibles assets are not identified or they are negotiated as a whole or as a value of goodwill with the consequences that they are either overvalued or undervalued, bringing about enterprise profits or losses. This paper shows the behavior of negotiations of intangible assets, particularly in the international biopharmaceutical industry. The experience of Great Britain and France is given, since these countries have achieved the highest intangible assets identification (37 %), followed by the United States. Among the developing countries, only South Africa and China have identified a representative percentage of intangible assets. The most highly negotiated contracts are those of research and development, followed by licensing agreements and acquisitions. Manufacturing agreements prevail in south-south cooperation. In Cuba the biotechnology sector, as a model of high tech enterprises, shows great strength in novel technologies and unique patented products, which must not only be protected as intellectual property, but they must also be valued and appropriately negotiated. Therefore, a diagnostic study on the negotiation of intangible assets in the biotechnology sector is required, and therefore, a proposal of a strategy for their negotiation.

REFERENCES

1. Drucker P. La sociedad postcapitalista. Bogotá, Editorial Norma; 1994.

2. Karstetter E. How intangible assets affect business value. Enterpreneur [Internet]. 2002 May 6. [cited 2013 Aug 14]. Available from: http://www.entrepreneur.com/article/51628

3. IFRS 3 — Business Combinations [Internet]. London: Deloitte Touche Tohmatsu Limited. c. 2013 [cited 2013 Aug 14]. Available from: http://www.iasplus.com/ en/standards/ifrs/ifrs3

4. Financial Accounting Standard Board. Statement of Financial Accounting Standard Nº 141 (revised 2007). Business combinations [Internet]; Norwalk: Financial Accounting Standards Board ; 2010 [cited 2013 Aug 14]. Available from: http://www. fasb.org/cs/BlobServer?blobkey=id&blob where=1175823288072&blobheader=a pplication%2Fpdf&blobcol=urldata&blob table=MungoBlobs

5. Intangible Business [Internet]. London: Intangible Business Limited. c. 2003-2013 [cited 2013 Aug 14]. Available from: http://www.intangiblebusiness.com/

6. Forbes T. Shareholders None the Wiser as SFAS 141 has a minimal impact. Intangible Assets Manage. 2008 Feb [cited 2013 Aug 14]:8-12. Available from: http://www.intangiblebusiness.com/ uploads/2013/02/11/358-Stakeholders_ none_the_wiser_as_SFAS141_has_minimal_ impact_IAM_February_2008.pdf

7. Fernández P. Valoración de marcas e intangibles. Universidad de Navarra, España; 2007.

8. Danzon P, Epstein A, Nicholson S. Mergers and acquisitions in the pharmaceutical and biotech industries. Manage Decis Econ. 2007;28(4-5):307-28.

9. Nicholson S, Danzon P, McCullough JS. Biotech-pharmaceutical alliances as a signal of asset and firm quality [Internet]. Massachusetts: National Bureau of Economic Research, Working Paper Series, Working Paper 9007; 2002 [cited 2013 Aug 14]. Available from: http://www.nber. org/papers/w9007.pdf

10. Los beneficios son mutuos en la nueva Ola de alianzas biotecnológicofarmacéuticas. [Internet]. Philadelphia: Universia Knowledge@Wharton; 2003 [cited 2013 Aug 14]. Available from: http://knowledge.wharton.upenn.edu/ article/the-benefits-are-mutual-in-newwave- of-biotechpharma-alliances/

11. Lage A. La Economía del Conocimiento y el Socialismo. La Habana: Editorial Academia; 2013.

12. Biopharmaceutiques Internet. Puteaux Cedex: PR Editions; c2009 [cited 2013 Aug 14]. Available from: http://www.biopharmaceutiques. com/en/tables/agreements/ index.html

13. Castro Ruz F. Discurso pronunciado por el comandante Fidel Castro Ruz, primer ministro del gobierno revolucionario, en el acto celebrado por la Sociedad Espeleológica de Cuba, en la Academia de Ciencias, el 15 de enero de 1960. Versiones taquigráficas. La Habana: Consejo de Estado; 1960 [cited 2013 Jan 5]. Available from: www.cuba.cu/gobierno/discursos/1960/ esp/f150160e.html

14. López E, Silva R, Acevedo B, Buxadó JA, Aguilera A, Herrera L. Biotechnology in Cuba: 20 years of scientific social and economic progress. J Commer Biotechnol. 2006;13(1):1-11.